Health News Review
  • Apr 16 2013

    Generic statins now “a market commodity, no different from grains of rice or sugar”

    Some drug stores in the US are now giving away statin drugs for cholesterol. The Philadelphia Inquirer reported on a chain in its area doing so: “Retail grocery store competition is fierce, and Wegmans is trying to get an edge by giving away – yes, free – a generic version of what was the world’s [...]

    No Comments
  • Apr 4 2013

    Drug marketing blamed for increase in ADHD diagnoses

    A Minneapolis-area psychiatrist, Charles Dean, published an opinion piece in the Star Tribune, “Rise in ADHD cases is due to marketing.“ It appeared adjacent to the Strib’s republishing of the NYT op-ed piece, “Diagnosis:  Human,” by Ted Gup – that we blogged about yesterday. Dr. Dean writes: “The 53 percent increase in the diagnosis of [...]

  • Apr 3 2013

    Personal reflection on DSM V: “being human is itself fast becoming a condition”

    An op-ed worth reading in the New York Times – “Diagnosis:  Human.” Journalist-author Ted Gup, a fellow of the Edmond J. Safra Center for Ethics at Harvard University, tells the tragic story of his son, one of the “11 percent of school-age children (who) now receive a diagnosis of attention deficit hyperactivity disorder — some [...]

  • Feb 13 2013

    Some stuff you may not want to hear about why your doctor chooses certain drugs

    Drug companies clearly have a lot riding on understanding doctors’ prescribing behavior and how they assign trust to brands and to specific drugs. A Harris Poll of physicians found that: “…when it comes to driving trust, emotional connection, relationships with sales representatives, and perceptions of the pharmaceutical company or companies backing the product can be [...]

    No Comments
  • Feb 11 2013

    Oh No! No disclosure of Ohno drug company payment

    Olympian Apolo Anton Ohno is a marketable commodity. And drug company Teva Pharmaceuticals is riding those fast blades for all it can. And media love reporting on how Ohno is now the “national face” of the exercise-induced brochospasm campaign sponsored by Teva, which gives the condition the acronym label of EIB. Acronyms are hot in [...]

    No Comments
  • Feb 7 2013

    David Healy’s depressing reflection on 25th anniversary of Prozac & SSRIs for depression

    Psychiatrist-author David Healy blogs about “Prozac and SSRIs:  Twenty-fifth Anniversary.” In his post, he touches on: the phenomenal explosion in the use of antidepressants suicides triggered by antidepressant use birth defects and miscarriages from antidepressants used in pregnancy “the dead doctor sketch” – what antidepressant prescribing has done to the practice of medicine and to [...]

    1 Comment
  • Feb 3 2013

    A few health care news gems from the past week that you may have missed

    The New Yorker profile of Dr. Oz, “The Operator: Is the most trusted doctor in America doing more harm than good?” The NPR piece, “Hanging A Price Tag On Radiology Tests Didn’t Change Doctors’ Habits.”’s new Drug Ads teaching tool.  It’s a three-part slideshow covering misleading advertising in  medical journals, indirect marketing, and disease-mongering; [...]

    No Comments
  • Feb 2 2013

    Bad Pharma (the book) comes to the US

    British physician and writer Ben Goldacre is on a North American tour.  His book, “Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients,” is released in the US on February 5. The book has been discussed in The Economist, The Public Library of Science blogs, The Guardian, and elsewhere. (Addendum one day later:  Carl [...]

    1 Comment
  • Jan 25 2013

    Ghostwriting part 3: psych drug Paxil – and conclusion

    The GlaxoSmithKline psychiatric drug Paxil is the topic of the third and final part of a series of unsolicited guest blog submissions by Jonathan Leo, PhD, and Jeffrey Lacasse, PhD. ——————————— Paxil, GlaxoSmithKline, and the University of Pennsylvania In June of 2012 charges of ghostwriting were made by a University of Pennsylvania Professor over a [...]

  • Jan 24 2013

    Ghostwriting series part 2: Medtronic’s InFuse spinal fusion surgery product

    In the second part of their 3-part guest blog series on ghostwriting of medical papers, researchers Jonathan Leo, PhD, and Jeffrey Lacasse, PhD address “Medtronics, InFuse and the University of Wisconsin.” —————————————– InFuse, manufactured by Medtronic and approved by the FDA in 2002, is used for promoting the growth of bone graft material during surgery.  [...]

    1 Comment